Meunier F. (1996) Current clinical issues on mycoses in neutropenic patients. International Journal of Antimicrobial Agents 6:135-140.
Orosz S.E., Frazier D.L. (1995) Antifungal agents: A review of their pharmacology and therapeutic indications. Journal of Avian Medicine and Surgery 9:8-18.
Odom R.B. (1996) New therapies for onychomycosis. Journal of the American Academy of Dermatology 35.
Odds F.C. (1993) Resistance of yeasts to azole-derivative anti-fungals. Journal of Antimicrobial Chemotherapy 31:463-471.
Sugar A.M. (1993) Fluconazole and itraconazole: Current status and prospects for antifungal therapy. Current Clinical Topics in Infectious Diseases 13:74-98.
Van Cutsem J., Van Gerven F., Janssen P.A. (1987) Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: Animal models. Reviews of Infectious Diseases 9(SUPPL. 1).
Van Cutsem J. (1989) The in-vitro antifungal spectrum of itraconazole. Mycoses 32(SUPPL. 1):7-13.
Boogaerts M.A., Verhoef G.E., Zachee P., Demuynck H., Verbist L., De Beule K. (1989) Antifungal prophylaxis with itraconazole in prolonged neutropenia: Correlation with plasma levels. Mycoses 32(SUPPL. 1):103-108.
De Beule K. (1996) Itraconazole: Pharmacology, clinical experience and future development. International Journal of Antimicrobial Agents 6:175-181.
Pittet D., Monod M., Suter P.M., Frenk E., Auckenthaler R. (1994) Candida colonization and subsequent infections in critically ill surgical patients. Annals of Surgery 220:751-758.
Menichetti F., Del Favero A., Martino P., Bucaneve G., Micozzi A., Girmenia C. (1999) Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial. Clinical Infectious Diseases 28:250-255.
Morgenstern G.R., Prentice A.G., Prentice H.G., Ropner J.E., Schey S.A., Warnock D.W. (1999) A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. British Journal of Haematology 105:901-911.
Harousseau J.L., Dekker A.W., Stamatoullas-Bastard A., Fassas A., Linkesch W., Gouveia J. (2000) Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial comparing amphotericin B. Antimicrobial Agents and Chemotherapy 44:1887-1893.
Huijgens P.C., Simoons-Smith A.M., van Loenen A.C., Prooy E., van Tinteren H., Ossenkoppele G.J. (1999) Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. Journal of Clinical Pathology 52:376-380.
Barone J.A., Moskovitz B.L., Guarnieri J., Hassell A.E., Colaizzi J.L., Bierman R.H. (1998) Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 18:295-301.
Van de Velde V.J., Van Peer A.P., Heykants J.J., Woestenborghs R.J.H., Van Rooy P., De Beule K.L. (1996) Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy 16:424-428.
Rex J.H., Pfaller M.A., Galgiani J.N., Bartlett M.S., Espinel-Ingroff A., Ghannoum M.A. (1997) Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual frame-work and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clinical Infectious Diseases 24:235-247.
Levron J.C., Chwetzoff E., Le Moing J.P., Lappereau-Gallot A., Chrétien P. (1998) Lack of interaction of antacid drug omeprazole on the bioavailability of itraconazole oral solution. Blood , Abstract 3205; 92(SUPPL. 1):546.
